厄贝沙坦与福辛普利影响慢性心力衰竭患者左室重塑和心功能的对照研究  

Comparative study of Irbesartan and Fosinopril Leigh on left ventricular remodeling and cardiac function in CHF patients

作　　者：王玉竹 陈友魁 Wang Yuzhu;Chen Youkui(Department of internal medicine,Luodian people＇s Hospital,Qiannan,Guizhou,550199,China)

机构地区：[1]罗甸县人民医院内科,贵州黔南550199

出　　处：《当代医学》2018年第25期78-80,共3页Contemporary Medicine

摘　　要：目的比较厄贝沙坦与福辛普利对慢性心力衰竭(CHF)患者的左室重塑和心功能的影响,并进行分析。方法选取本院2017年2月~2018年2月收治的112例CHF患者作为研究对象,采用随机数字法分为A组和B组,各56例,其中A组在常规治疗基础上给予厄贝沙坦治疗,B组则在常规治疗基础上给予福辛普利治疗,观察记录并比较两组患者的临床疗效、左心室重塑指标以及心功能指标。结果治疗3个月后,A组临床总有效率89.29%稍高于B组的87.50%,但差异无统计学意义。两组患者治疗前左室重塑的指标比较差异无统计学意义;治疗后两组左室重塑指标均较治疗前有显著改善,差异有统计学意义(P<0.05),但组间比较差异无统计学意义。两组治疗前心功能指标比较差异无统计学意义;治疗后3个月,两组心功能指标较治疗前均有显著改善,差异均有统计学意义(P<0.05),但组间比较差异无统计学意义。结论厄贝沙坦与福辛普利在用药后均能够显著提高CHF患者的治疗效果,并能促进患者的左室重塑和心功能恢复。Objective To compare the effects of Irbesartan and Fosinopril Leigh on left ventricular remodeling and cardiac function in patients with chronic heart failure （CHF）. Methods 112 cases of CHF patients treated in our hospital from February 2017 to February 2018 were selected as the research subjects, and they were divided into group A and group B by random number method, with 56 cases in each group. Group Awas treated with Irbesartan on the basis of routine treatment, and group B was given Fosinopril Leigh treatment on the basis of routine treatment, and the two groups were treated for 3 months continuously. The clinical efficacy, left ventricular remodeling index and cardiac function of the two groups were observed and compared. Results After 3 months of treatment, the total effective rate of group A was 89.29%, higher than that of group B 87.50%, but the difference was not statistically significant. There was no significant difference in left ventricular remodeling between the two groups before treatment. After treatment, two groups of indicators were significantly improved than before treatment, the difference was statistically significant （P 〈 0.05）, but there was no significant difference between the two groups. There was no significant difference in cardiac function between the two groups before treatment. The two groups in the 3 months after treatment were significantly improved than before treatment, and the differences were statisticallysignificant （P〈0.05）, but there was no statistical difference between the two groups. Conclusion Irbesartan and FosinoprilLeighcansignificantly improve the therapeutic effect of patients with chronic heart failure （CHF） after medication, and can also promote the remodeling of left ventri-le and the recovery of cardiac function.

关 键 词：厄贝沙坦 福辛普利 慢性心力衰竭 左室重塑 心功能 对比研究 

分 类 号：R541.6[医药卫生—心血管疾病]